Form 4: Amedisys Director Julie D. Klapstein Reports Acquisition of Restricted Stock Units

Director Julie D. Klapstein reports the acquisition of 1,678 restricted stock units in Amedisys Inc.

Summary

• On May 3, 2024, Julie D. Klapstein, a director of Amedisys Inc., acquired 1,678 time-based Restricted Stock Units (RSUs).
• Each RSU represents a contingent right to receive one share of Amedisys' common stock.
• The RSUs will vest 100% on May 3, 2025, contingent upon Klapstein's continued service as a non-employee member of the Issuer's Board of Directors.
• Following the transaction, Klapstein directly owns 14,341 shares of Amedisys Inc. common stock.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive as it reflects standard executive compensation practices and aligns director interests with shareholders.

Positives

• The acquisition of restricted stock units aligns the director's interests with those of the shareholders, incentivizing continued service and contribution to the company's success.

Future Outlook

The director's continued service is predicated on the vesting of the restricted stock units on May 3, 2025.

Industry Context

Form 4 filings are standard disclosures required by the SEC to provide transparency regarding the transactions of company insiders, such as directors and officers, in their company's stock.

Stakeholder Impact

• The acquisition of restricted stock units by a director can positively influence shareholder confidence by aligning management's interests with those of the shareholders.

Key Dates